- Active not recruitingPHASE2
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
This study is checking a new medicine called AOC 1020 for people with Facioscapulohumeral Muscular Dystrophy (FSHD). It's for people who were in an earlier study of this medicine. The aim is to see if it's safe and helps over a longer time.
For: FSHD · FSHD1 · FSHD2United States · Canada · United Kingdom - RecruitingPHASE3
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
This study is testing a new medicine called del-brax for people with Facioscapulohumeral Muscular Dystrophy (FSHD). Researchers want to see if it's safe and effective in improving or slowing down the condition. It involves receiving treatment every six weeks for over a year.
For: Facioscapulohumeral Muscular Dystrophy · FSHD · FSHD - Facioscapulohumeral Muscular DystrophyUnited States · Canada · Denmark